Ann Ital Chir. 2021;92:728-731.
The development of acute pancreatitis is multifactorial requiring predisposition and relevant injury.Viral acute pancreatitis has been described in other viral infections.However, pancreatic involvement in SARS-CoV-2 infection is still poorly defined.The present comparative study reports the patients with acute pancreatitis during the COVID-19 pandemic and last year covering the same period to appraise the link between COVID-19 and acute biliary pancreatitis.
The retrospective observational study was conducted in acute biliary pancreatitis patients from 13.03.19to13.09.19 and from 13.03.20to13.09.20 respectively.
The study included 181patients(105patients in 2019;76 patients in 2020(during COVID-19 pandemic)).The patients were named as Group A(Normal period)and GroupB(Pandemic period),respectively.The groups were found to be comparable as there was no significant difference between the mean age, sex, comorbidities, cholecystectomized, and recurrency. There is no significant difference in the laboratory and radiological findings of GroupA and GroupB. However, there is a significant difference between the COVID-19 positive and negative patients in GroupB in terms of Glucose levels(p=0,025)and the presence of edema or necrosis in radiological images(p=0,046).There is a significant difference between the patients' number with abdominal pain of acute biliary pancreatitis in 2019and2020.(p=0)The length of stay was statistically significant in COVID-19 positive patients.(p= 0,013) CONCLUSIONS: Clinicians involved in the management of acute pancreatitis should be aware of its existence in the context of COVID-19.Understanding of the disease process and clinical manifestations of COVID-19 is still developing.Awareness of these issues and addressing them adequately will be crucial for the management.
Acute Biliary Pancreatitis, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
急性胰腺炎的发生是多因素的，需要有易患因素和相关损伤。在其他病毒感染中已描述了病毒性急性胰腺炎。然而，SARS-CoV-2 感染中的胰腺受累仍未得到明确界定。本比较研究报告了 COVID-19 大流行期间和去年同期的急性胰腺炎患者，以评估 COVID-19 与急性胆源性胰腺炎之间的联系。
本回顾性观察性研究分别纳入了 19 年 3 月 13 日至 9 月 13 日和 20 年 3 月 13 日至 9 月 13 日的急性胆源性胰腺炎患者。
本研究纳入了 181 例患者（19 年 105 例患者；20 年 76 例患者（COVID-19 大流行期间））。患者分别命名为 A 组（正常时期）和 B 组（大流行时期）。两组在平均年龄、性别、合并症、胆囊切除术和复发率方面无显著差异。A 组和 B 组的实验室和影像学检查结果无显著差异。然而，B 组中 COVID-19 阳性和阴性患者的血糖水平（p=0.025）和影像学图像中的水肿或坏死存在情况（p=0.046）存在显著差异。19 年和 20 年急性胆源性胰腺炎患者腹痛人数存在显著差异（p=0）。COVID-19 阳性患者的住院时间具有统计学意义（p=0.013）。
参与急性胰腺炎管理的临床医生应意识到其在 COVID-19 大流行背景下的存在。对 COVID-19 疾病过程和临床表现的认识仍在不断发展。了解这些问题并充分解决这些问题对于管理至关重要。
急性胆源性胰腺炎，COVID-19，严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）。
